Status:
TERMINATED
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
Lead Sponsor:
Imperial College London
Conditions:
Influenza
SARS (Severe Acute Respiratory Syndrome)
Eligibility:
All Genders
18+ years
Brief Summary
Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell. Influenza ('flu') is one of the ...
Detailed Description
Despite clinical advances and decades of research, the ability to reliably predict the course of respiratory viral diseases such as influenza and coronavirus infections remains poor. The aim of this p...
Eligibility Criteria
Inclusion
- Healthy persons aged ≥ 18, and able to give informed consent
- Patient is admitted to hospital
- Primary reason for hospital admission is clinical suspicion of a new episode of ARI
- Onset of the following symptoms within the last 7 days: i. Sudden onset of self-reported fever OR temperature of ≥ 38°C at presentation AND ii. At least one respiratory symptom (cough, sore throat, runny or congested nose, dyspnoea) AND iii. At least one systemic symptom (headache, muscle ache, sweats or chills or tiredness).
Exclusion
- Patient lacks capacity to provide informed consent
- Patient has been transferred from another hospital
- Patient has been previously enrolled in the study
Key Trial Info
Start Date :
January 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04664075
Start Date
January 25 2021
End Date
April 30 2022
Last Update
May 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College London
London, United Kingdom